Ilenia M.
- Country
- Italy
- Department
- DIPARTIMENTO Di EMATOLOGIA
Research Overview
Data & Insights
Has run more than one trial at 25 of 65 partner sites.
Specializations
Hematologic Malignancies
Investigator concentrates on cancers originating in blood and lymphoid tissues.
- Acute Myeloid Leukemia with NPM1 mutation
- Acute Lymphoblastic Leukemia (Philadelphia chromosome‑positive and negative)
- Diffuse Large B‑Cell Lymphoma (including elderly and ABC subtypes)
- Follicular Lymphoma
- Hodgkin’s Lymphoma
Therapeutic approaches integrate targeted agents, monoclonal antibodies, and chemo‑immunotherapy regimens.
Solid Tumor Oncology
Investigator addresses major solid cancers with emphasis on advanced and metastatic disease.
- Non‑Small Cell Lung Cancer
- Colorectal Cancer (RAS/BRAF wild‑type, KRAS G12C)
- Breast Cancer (ER‑positive/HER2‑negative, triple‑negative, PD‑L1 positive)
- Ovarian Cancer (BRCA wild‑type)
- Muscle‑Invasive Bladder Cancer
Focus includes adjuvant strategies, metastatic control, and biomarker‑driven patient selection.
Targeted Molecular Therapies
Investigator explores therapies directed at specific oncogenic alterations.
- KRAS G12C inhibition
- EGFR mutation targeting
- HER2 mutation or amplification strategies
- MET over‑expression or amplification
- NPM1 mutation‑specific approaches
Efforts aim to match molecular profiles with precision agents to improve response durability.
Immunotherapy and Checkpoint Inhibition
Investigator evaluates immune‑modulating treatments across hematologic and solid cancers.
- PD‑L1 blockade (e.g., atezolizumab)
- TIGIT inhibition (e.g., tiragolumab)
- PD‑1 pathway targeting (e.g., pembrolizumab)
- CD20 directed antibodies (e.g., rituximab)
- CDK 4/6 inhibition combined with endocrine therapy
Research seeks synergistic combinations that enhance anti‑tumor immunity while managing toxicity.
Rare Hematologic Disorders
Investigator is involved in clinical studies of uncommon blood diseases with high unmet need.
- Paroxysmal Nocturnal Hemoglobinuria
- Immune‑mediated Thrombotic Thrombocytopenic Purpura
- Transplant‑associated Thrombotic Microangiopathy
- warm Autoimmune Hemolytic Anemia
- High‑Risk Non‑muscle‑invasive Bladder Cancer
Clinical work emphasizes novel complement inhibition, targeted immunosuppression, and disease‑modifying therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.